We provide strategic IPO advisory services, delivering comprehensive support to ensure both listing readiness and successful execution. Our approach encompasses financial structuring, regulatory alignment, and market positioning, enabling organizations to navigate the complexities of public offerings with confidence and precision.
In addition, we strengthen investor relations by building the institutional depth necessary to attract specialized venture capital. Through dedicated board and executive support—including CFO and advisory functions—we enhance corporate governance frameworks and ensure alignment with international standards, positioning companies for sustainable growth and credibility in global markets.
We provide essential, hands-on guidance for navigating the complex regulatory landscapes of the TSX, TSX-V, and CSE. Our team specializes in translating Korean innovation into North American market standards, managing everything from IFRS financial conversions to disclosure-based exchange requirements. By bridging these two distinct financial worlds, we ensure your listing process is technically sound and strategically optimized for the Canadian ecosystem.
We help firms transition from “The Waiting Game” of restricted domestic windows to “The Global Leap” into high-liquidity North American markets. Instead of facing structural funding scarcity and valuation discounts at home, we position your company to access specialized biopharma investors who value early-stage R&D. This shift allows your firm to be re-rated against global benchmarks, unlocking the capital necessary for massive clinical scale.
Our proven 18-month strategic framework is a phased approach that moves companies from initial exchange clarity to full institutional readiness. We manage the entire lifecycle: from the first 4 months of public entry via TSX-V or CSE, to the mid-term focus on capital quality and liquidity. The roadmap culminates in a strategic uplit and market re-rating, providing a predictable path to growth that typically takes over a decade in domestic markets.
We leverage Canada’s unique ecosystem as a premier gateway to the US and European capital markets for growth-stage science. By facilitating early public entry—even for pre-revenue and pre-IND firms—we enable companies to secure the massive capital injections required for North American clinical trials. This global visibility on world-class senior exchanges ensures your company is positioned for long-term success and premium valuations on the world stage.
At Kowest Capital, our mission is to empower Korean Life Science SMEs by bridging the gap between domestic innovation and North American capital. We recognize that for many promising biotech and digital health firms, the path to growth is often blocked by structural challenges in local markets. We provide the strategic roadmap and professional expertise necessary to unlock deep liquidity on Canadian exchange platforms, ensuring your science has the funding it deserves.